On January 21, 2025 Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, reported advancements in its intellectual property portfolio through the acquisition and expansion of patent applications to its innovative therapeutic pipeline (Press release, Hoth Therapeutics, JAN 21, 2025, View Source [SID1234649806]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

These newly secured patents reflect Hoth’s commitment to pioneering cutting-edge treatments that address unmet medical needs, with a focus on enhancing therapeutic efficacy and broadening applications across various disease areas.

"Our expanding intellectual property portfolio supports Hoth’s position as a leader in innovative drug development," said Robb Knie, CEO of Hoth Therapeutics. "These provisional patent applications reinforce our proprietary approaches and our mission to deliver breakthrough therapies that improve patients’ lives."

Hoth Therapeutics continues to invest in robust research and development strategies, ensuring the protection and growth of its proprietary technologies. The company remains dedicated to advancing its pipeline and delivering impactful healthcare solutions.